Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 21 05 2019
accepted: 04 07 2019
pubmed: 13 7 2019
medline: 29 12 2020
entrez: 13 7 2019
Statut: ppublish

Résumé

Prostate cancer care in the Middle East is highly variable and access to specialist multidisciplinary management is limited. Academic tertiary referral centers offer cutting-edge diagnosis and treatment; however, in many parts of the region, patients are managed by non-specialists with limited resources. Due to many factors including lack of awareness and lack of prostate-specific antigen (PSA) screening, a high percentage of men present with locally advanced and metastatic prostate cancer at diagnosis. The aim of these recommendations is to assist clinicians in managing patients with different levels of access to diagnostic and treatment modalities. The first Advanced Prostate Cancer Consensus Conference (APCCC) satellite meeting for the Middle East was held in Beirut, Lebanon, November 2017. During this meeting a consortium of urologists, medical oncologists, radiation oncologist and imaging specialists practicing in Lebanon, Syria, Iraq, Kuwait and Saudi Arabia voted on a selection of consensus questions. An additional workshop to formulate resource-stratified consensus recommendations was held in March 2019. Variations in practice based on available resources have been proposed to form resource-stratified recommendations for imaging at diagnosis, initial management of localized prostate cancer requiring therapy, treatment of castration-sensitive/naïve advanced prostate cancer and treatment of castration-resistant prostate cancer. This is the first regional consensus on prostate cancer management from the Middle East. The following recommendations will be useful to urologists and oncologists practicing in all areas with limited access to specialist multi-disciplinary teams, diagnostic modalities and treatment resources.

Identifiants

pubmed: 31297628
doi: 10.1007/s00345-019-02872-x
pii: 10.1007/s00345-019-02872-x
pmc: PMC7064460
doi:

Substances chimiques

Androgen Antagonists 0
Antineoplastic Agents 0
Antineoplastic Agents, Hormonal 0
Benzamides 0
Nitriles 0
Docetaxel 15H5577CQD
Phenylthiohydantoin 2010-15-3
enzalutamide 93T0T9GKNU
KLK3 protein, human EC 3.4.21.-
Kallikreins EC 3.4.21.-
Prostate-Specific Antigen EC 3.4.21.77
Abiraterone Acetate EM5OCB9YJ6

Types de publication

Consensus Development Conference Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

681-693

Références

J Glob Oncol. 2018 Jul;4:1-8
pubmed: 30110223
N Engl J Med. 2018 Jun 28;378(26):2465-2474
pubmed: 29949494
J Clin Oncol. 2018 May 10;36(14):1389-1395
pubmed: 29590007
Einstein (Sao Paulo). 2019 Mar 07;17(2):eGS4414
pubmed: 30843996
Clin Prostate Cancer. 2002 Dec;1(3):145-52
pubmed: 15046689
Lancet Oncol. 2016 Jun;17(6):747-756
pubmed: 27160475
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
N Engl J Med. 2017 Feb 2;376(5):417-428
pubmed: 28146658
Lancet. 2018 Dec 1;392(10162):2353-2366
pubmed: 30355464
Pract Radiat Oncol. 2018 Nov - Dec;8(6):354-360
pubmed: 30322661
Eur Urol. 2014 Dec;66(6):1116-24
pubmed: 25052213
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Prostate. 2014 Feb;74(2):210-6
pubmed: 24132735
JAMA. 2017 Jan 3;317(1):48-58
pubmed: 28030702
Cancer. 2016 Jul 1;122(13):2004-11
pubmed: 27028170
Eur Urol. 2016 Jun;69(6):1142-8
pubmed: 26749093
Eur Urol. 2018 Mar;73(3):436-444
pubmed: 28779974
Lancet. 2011 Mar 5;377(9768):813-22
pubmed: 21353695
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
Eur Urol. 2020 Apr;77(4):403-417
pubmed: 30773328
J Clin Oncol. 2018 Aug 20;36(24):2492-2503
pubmed: 29985747
J Clin Oncol. 2007 May 20;25(15):2035-41
pubmed: 17513807
Contemp Clin Trials. 2015 May;42:26-40
pubmed: 25749312
Eur Urol. 2018 Feb;73(2):178-211
pubmed: 28655541
Osteoporos Int. 2017 Jan;28(1):127-137
pubmed: 27650643
Ann Oncol. 2018 May 1;29(5):1235-1248
pubmed: 29529169
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
J Clin Oncol. 2019 May 10;37(14):1159-1168
pubmed: 30860948
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
Eur Urol. 2018 Oct;74(4):432-441
pubmed: 29980331
J Urol. 2017 Mar;197(3 Pt 1):662-668
pubmed: 27614333
J Natl Cancer Inst. 2004 Jun 2;96(11):879-82
pubmed: 15173273
Cancer Med. 2016 Jan;5(1):136-41
pubmed: 26628287
J Clin Epidemiol. 2014 Apr;67(4):401-9
pubmed: 24581294
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
N Engl J Med. 2019 Mar 28;380(13):1235-1246
pubmed: 30763142
Radiat Oncol. 2017 Sep 7;12(1):149
pubmed: 28882187
Crit Rev Oncol Hematol. 2014 Apr;90(1):36-48
pubmed: 24289901
N Engl J Med. 2018 Jun 28;378(26):2542
pubmed: 29949495

Auteurs

Deborah Mukherji (D)

Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, Lebanon. Dm25@aub.edu.lb.

Bassem Youssef (B)

Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon.

Christelle Dagher (C)

Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, Lebanon.

Albert El-Hajj (A)

Division of Urology, Department of Surgery, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, Lebanon.

Rami Nasr (R)

Division of Urology, Department of Surgery, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, Lebanon.

Fadi Geara (F)

Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon.

Danny Rabah (D)

Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Saad Al Dousari (S)

Department of Surgery, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.

Rabih Said (R)

Division of Hematology/Oncology, Department of Internal Medicine, Saint Georges Hospital University Medical Center, Beirut, Lebanon.

Raja Ashou (R)

Department of Radiology, Saint Georges Hospital University Medical Center, Beirut, Lebanon.

Wassim Wazzan (W)

Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon.

Michel Jabbour (M)

Division of Urology, Department of Surgery, Saint Georges Hospital University Medical Center, Beirut, Lebanon.

George Farha (G)

Department of Radiation Oncology, Mount Lebanon Hospital, Faculty of Medicine-University of Balamand, Beirut, Lebanon.

Nibras Al Hamdani (N)

Department of Surgery, Medical City Teaching Hospital Baghdad, Baghdad, Iraq.

Yousuf Al Hallaq (Y)

Department of Surgery, Medical City Teaching Hospital Baghdad, Baghdad, Iraq.

Hassan Ghazal (H)

Division of Hematology/Oncology, Department of Internal Medicine, Clemenceau Medical Center, Beirut, Lebanon.

Haifa Dbouk (H)

Division of Oncology, Jamal Amel Hospital, Tyre, Lebanon.

Bassel Bachir (B)

Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon.

Clement El Khoury (C)

Department of Radiation Oncology, Hotel Dieu de France, Saint Joseph University Faculty of Medicine, Beirut, Lebanon.

Ghazi Sakr (G)

Division of Urology, Department of Surgery, Mount Lebanon Hospital, Beirut, Lebanon.

Hero K Hussain (HK)

Department of Radiology, American University of Beirut Medical Center, Beirut, Lebanon.

Khaled Sayyid (K)

Department of Surgery, Makassed Hospital, Beirut, Lebanon.

Khaled Ibrahim (K)

Division of Hematology/Oncology, Department of Internal Medicine, Hammoud Hospital University Medical Center, Saida, Lebanon.

Mohammad Haidar (M)

Department of Radiology, American University of Beirut Medical Center, Beirut, Lebanon.

Nicolas Zouain (N)

Department of Radiation Oncology, Clemenceau Medical Center, Beirut, Lebanon.

Nizar Bitar (N)

Division of Hematology/Oncology, Department of Internal Medicine, Sahel General Hospital, Beirut, Lebanon.

Walid Alameh (W)

Department of Surgery, Sahel General Hospital, Beirut, Lebanon.

Fadi Abbas (F)

Middle East Tumor Institute, Beirut, Lebanon.

Sami Faddoul (S)

Doctors Center Radiology, Beirut, Lebanon.

Elie Nemer (E)

Department of Urology, Saint Joseph University, Beirut, Lebanon.

Georges Assaf (G)

Division of Urology, Department of Surgery, Saint Georges Hospital University Medical Center, Beirut, Lebanon.

Fadi Farhat (F)

Division of Hematology/Oncology, Department of Internal Medicine, Hammoud Hospital University Medical Center, Saida, Lebanon.

Muhammad Bulbul (M)

Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon.

Sally Temraz (S)

Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, Lebanon.

Ali Shamseddine (A)

Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, Lebanon.

Silke Gillessen (S)

Division of Cancer Sciences, University of Manchester and the Christie, Manchester, UK.
Department of Medical Oncology and Haematology, Cantonal Hospital Saint Gallen, University of Bern, Bern, Switzerland.

Aurelius Omlin (A)

Department of Medical Oncology and Haematology, Cantonal Hospital Saint Gallen, University of Bern, Bern, Switzerland.

Raja Khauli (R)

Division of Urology, Department of Surgery, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, Lebanon. rkhauli@aub.edu.lb.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH